Navigation Links
Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors
Date:6/1/2009

- Results Presented at American Society of Clinical Oncology (ASCO) Meeting Show Fleximer(R) Conjugated Drug Is Well Tolerated with Favorable Pharmacokinetics and Prolonged Stable Disease in Refractory Tumors -

CAMBRIDGE, Mass., June 1 /PRNewswire/ -- Mersana Therapeutics presented preliminary results of a Phase 1 clinical trial for its lead development candidate, XMT-1001, in a poster session at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando. XMT-1001 is a broad-spectrum cytotoxic, based on camptothecin (CPT), conjugated to Mersana's biodegradable polymer platform, Fleximer(R).

Ten of 37 evaluable patients dosed to date demonstrated evidence of stable disease and seven patients had prolonged stable disease for at least 12 weeks. The study has also demonstrated that XMT-1001 can be safely given to patients. Toxicities such as hemorrhagic cystitis and serious diarrhea were not observed in this preliminary assessment. In addition, a favorable pharmacokinetic profile was observed. Full text of the abstract can be viewed online at the ASCO website at www.abstract.asco.org.

"We are encouraged by the favorable safety and pharmacokinetic profile demonstrated by XMT-1001 thus far," said Julie Olson, Chief Executive Officer of Mersana. "These preliminary results build on our preclinical studies, which showed that XMT-1001 has greater efficacy in human tumor xenograft models than comparable doses of irinotecan, an agent with a similar mechanism of action as camptothecin and that is approved to treat patients with colon cancer. We look forward to advancing XMT-1001 into a Phase 2 trial in a solid tumor indication."

About the XMT-1001 Preliminary Study

The Phase 1 trial is an open label, dose escalation study of XMT-1001 administered as an IV infusion once every three weeks in patients with advanced solid tumors. The objectives of the study are to determine the maximum tolerated dose (MTD) as well as to assess safety and pharmacokinetics. The maximum tolerated dose is not yet defined and accrual to the study continues.

ASCO Poster Information

"A Phase I study of the safety and pharmacokinetics (PK) of XMT-1001 given as an intravenous (IV) infusion once every three weeks to patients with advanced solid tumors."

By E. Sausville, L. Garbo, G. J. Weiss, S. Anthony, D. Shkolny, A. V. Yurkovetskiy, C. Bethune, R. J. Fram; University of Maryland, Baltimore, MD; New York Oncology Hematology, Albany, NY; TGen Clinical Research Services, Scottsdale, AZ; Mersana Therapeutics, Inc., Cambridge, MA; Covance Bioanalytical, Madison, WI

    Session: Developmental Therapeutics: Cytotoxic Chemotherapy
    Type: General Poster Session
    Time: Saturday May 30, 2009, 8:00 AM to 12:00 PM
    Location: Level 2, West Hall C

About Fleximer(R)

The key component of Mersana's platform is Fleximer(R), a novel, biodegradable and bio-inert polymer that can be chemically linked to small molecules and biologics. Fleximer(R) technology improves the therapeutic index of existing compounds by uniquely combining biodegradability with "biological stealth" properties, making Fleximer(R) materials and their conjugates long-circulating and non-immunotoxic. Fleximer(R) molecules are characterized by solubility in water, with stability in common manufacturing procedures.

About Mersana Therapeutics, Inc.

Mersana Therapeutics employs its biodegradable polymer platform (Fleximer(R)) to create new and better medicines. We are advancing our own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. We also leverage the versatility of Fleximer through partnerships to overcome the safety, efficacy, and delivery challenges of nucleic acids, biologics, and small molecules in numerous therapeutic areas.

Mersana is headquartered in Cambridge, MA and its investors include Fidelity Biosciences, ProQuest Investments, Rho Ventures, Harris & Harris Group and PureTech Ventures. For more information, visit www.mersana.com.

Fleximer(R) and Mersana(R) are registered trademarks of Mersana Therapeutics, Inc.


'/>"/>
SOURCE Mersana Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
2. Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. QMed, Inc. Reports July Medicare SNP Enrollments
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... California (PRWEB) , ... April 25, 2017 , ... ... Analytical Services and Metrology Partners.     , Covalent’s Analytical Services unit provides ... samples can be measured within 24 hours of receipt. There are no price ...
(Date:4/21/2017)... ... ... Having worked on the design of the innovative Triton™ lab bench ... design architects from around the country at the Lab Design Conference 2017 in Raleigh, ... Casey will be at the show, where they will highlight the unique elements of ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... to nourishing a range of emerging technology-based businesses, recently earned a $77,518 grant ... location. , Founded in 2004, FITCI is Frederick’s first incubator. A non-profit ...
(Date:4/20/2017)... ... April 20, 2017 , ... ... and clinical research community’s growing body of knowledge during its Eighth Annual ... Theatre and the adjacent Darling Atrium. During the event, undergraduates, graduate students, and ...
Breaking Biology Technology:
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... PUNE, India , March 23, 2017 The report ... Equipment, Touchless Biometric), Industry, and Geography - Global Forecast to 2022", published by ... growing at a CAGR of 29.63% between 2017 and 2022. ... ... Logo ...
(Date:3/22/2017)... 21, 2017   Neurotechnology , a provider ... today announced the release of the SentiVeillance ... improved facial recognition using up to 10 surveillance, ... computer. The new version uses deep neural-network-based facial ... it utilizes a Graphing Processing Unit (GPU) for ...
Breaking Biology News(10 mins):